Showing 561 - 580 results of 42,677 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (we decrease)) ))', query time: 0.71s Refine Results
  1. 561
  2. 562

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  3. 563

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  4. 564
  5. 565
  6. 566
  7. 567
  8. 568
  9. 569
  10. 570
  11. 571
  12. 572

    Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lun... by Feiyun Chang (12243382)

    Published 2022
    “…The regulation mechanism of circ_0017639 was demonstrated by a dual-luciferase reporter assay. We observed higher levels of circ_0017639 in DDP-resistant NSCLC samples and cells. …”
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  18. 578
  19. 579
  20. 580